217 related articles for article (PubMed ID: 27741213)
1. Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy.
Bychkovsky BL; Dizon DS; Sikov WM
Clin Obstet Gynecol; 2016 Dec; 59(4):756-771. PubMed ID: 27741213
[TBL] [Abstract][Full Text] [Related]
2. The triple-negative subtype: new ideas for the poorest prognosis breast cancer.
Curigliano G; Goldhirsch A
J Natl Cancer Inst Monogr; 2011; 2011(43):108-10. PubMed ID: 22043054
[TBL] [Abstract][Full Text] [Related]
3. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Freedman OC; Verma S; Clemons MJ
Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept.
Iwata H
Breast Cancer; 2011 Apr; 18(2):92-7. PubMed ID: 21140250
[TBL] [Abstract][Full Text] [Related]
5. [Systemic neoadjuvant therapy of luminal breast cancer in 2016].
Cottu PH
Bull Cancer; 2017 Jan; 104(1):69-78. PubMed ID: 27817858
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.
Houssami N; Macaskill P; von Minckwitz G; Marinovich ML; Mamounas E
Eur J Cancer; 2012 Dec; 48(18):3342-54. PubMed ID: 22766518
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
8. Hormone receptor and HER2 status: The only predictive factors of response to neoadjuvant chemotherapy in breast cancer.
Baulies S; Cusidó M; González-Cao M; Tresserra F; Fargas F; Rodríguez I; Úbeda B; Ara C; Fábregas R
J Obstet Gynaecol; 2015; 35(5):485-9. PubMed ID: 25383894
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant and Adjuvant Therapies for Breast Cancer.
Apuri S
South Med J; 2017 Oct; 110(10):638-642. PubMed ID: 28973704
[TBL] [Abstract][Full Text] [Related]
10. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer.
Chappuis PO; Goffin J; Wong N; Perret C; Ghadirian P; Tonin PN; Foulkes WD
J Med Genet; 2002 Aug; 39(8):608-10. PubMed ID: 12161606
[No Abstract] [Full Text] [Related]
11. Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
Steenbruggen TG; van Ramshorst MS; Kok M; Linn SC; Smorenburg CH; Sonke GS
Drugs; 2017 Aug; 77(12):1313-1336. PubMed ID: 28616845
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of the intrinsic molecular subtypes of breast cancer.
Prat A; Pineda E; Adamo B; Galván P; Fernández A; Gaba L; Díez M; Viladot M; Arance A; Muñoz M
Breast; 2015 Nov; 24 Suppl 2():S26-35. PubMed ID: 26253814
[TBL] [Abstract][Full Text] [Related]
13. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
14. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological features and treatment strategy for triple-negative breast cancer.
Yamamoto Y; Iwase H
Int J Clin Oncol; 2010 Aug; 15(4):341-51. PubMed ID: 20632057
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
[TBL] [Abstract][Full Text] [Related]
17. Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
Harbeck N
Breast; 2015 Nov; 24 Suppl 2():S44-8. PubMed ID: 26321480
[TBL] [Abstract][Full Text] [Related]
18. The predictive value of HER2 in breast cancer.
Piccart M; Lohrisch C; Di Leo A; Larsimont D
Oncology; 2001; 61 Suppl 2():73-82. PubMed ID: 11694791
[TBL] [Abstract][Full Text] [Related]
19. Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer.
Callari M; Cappelletti V; D'Aiuto F; Musella V; Lembo A; Petel F; Karn T; Iwamoto T; Provero P; Daidone MG; Gianni L; Bianchini G
Clin Cancer Res; 2016 Jan; 22(2):337-45. PubMed ID: 26423797
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
Silver DP; Richardson AL; Eklund AC; Wang ZC; Szallasi Z; Li Q; Juul N; Leong CO; Calogrias D; Buraimoh A; Fatima A; Gelman RS; Ryan PD; Tung NM; De Nicolo A; Ganesan S; Miron A; Colin C; Sgroi DC; Ellisen LW; Winer EP; Garber JE
J Clin Oncol; 2010 Mar; 28(7):1145-53. PubMed ID: 20100965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
